Loading…
Lobbying Income
$82.7M
Filings
1,819
Unique Clients
80
Active Period
2014–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Client: ASTELLAS PHARMA US, INC.
Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1
Consolidated Appropriations Act, 2026
2026 · third_quarter · Client: AMERICAN MEDICAL ASSOCIATION
NIH Strategic Plan. HIPAA Proposed Rule. Maternal health. Health care consolidation. ICD-11 implementation and other coding issues. Public Law 119-21: One Big Beautiful Bill Act. U.S. Preventive Services Task Force (USPSTF). AMA Physician Practice benchmark survey results. Vaccines and ACIP. Telehealth policy initiatives. H.R.7148: Consolidated Appropriations Act. Long-Term Care Rate Changes.
Client expense: — · Firm income: $60,000
Matched citations: H.R.7148
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5269
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Client: ASTRAZENECA PHARMACEUTICALS LP
CMMI GENEROUS Demo. Most Favored Nation (MFN). Implementation of the Inflation Reduction Act (IRA) including orphan drug exclusion. Issues related to the Medicare title in Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Issues relating to Medicare Parts B and D. Medicare Drug Price Negotiation Program. PBM Reform. 340B Rebate Model Pilot Program. H.R.9599: The SECURE 340B Act. Implementation of Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
Client expense: — · Firm income: $80,000
Matched citations: H.R.1
Clinical Trial Modernization Act
2026 · third_quarter · Client: ASTRAZENECA PHARMACEUTICALS LP
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.3521
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.5509
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
CMMI GENEROUS Demo. Most Favored Nation (MFN). Implementation of the Inflation Reduction Act (IRA) including orphan drug exclusion. Issues related to the Medicare title in Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Issues relating to Medicare Parts B and D. Medicare Drug Price Negotiation Program. PBM Reform. 340B Rebate Model Pilot Program. H.R.9599: The SECURE 340B Act. Implementation of Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
Client expense: — · Firm income: $80,000
Matched citations: H.R.9599
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: S.1862
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: S.2903
Clinical Trial Modernization Act
2026 · third_quarter · Client: ASTRAZENECA PHARMACEUTICALS LP
General issues related to rare disease and orphan drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Client expense: — · Firm income: $80,000
Matched citations: S.4440
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Client: AMGEN, INC.
Cardiovascular disease awareness and treatment. Bone disease awareness and treatment. Implementation of Inflation Reduction Act. Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).
Client expense: — · Firm income: $80,000
Matched citations: H.R.1
Maintaining Investments in New Innovation Act
2026 · third_quarter · Client: AMGEN, INC.
Drug pricing and patient affordability. Issues related to 340B. Biosimilars reimbursement and regulatory standards. Issues related to Supply Chain. H.R.1672: Maintaining Investments in New Innovation (MINI) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1672
H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.3160
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Client: AMGEN, INC.
Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.
Client expense: — · Firm income: $80,000
Matched citations: H.R.8800
H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.
Client expense: — · Firm income: $80,000
Matched citations: S.1553
Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.
Client expense: — · Firm income: $80,000
Matched citations: S.2
Secure Rural Schools Reauthorization Act of 2025
2026 · third_quarter · Client: CALIFORNIA SCHOOL BOARDS ASSOCIATION
General education issues. H.R.1383: Secure Rural Schools Reauthorization Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.1383
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Client: BRISTOL-MYERS SQUIBB COMPANY
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1492
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Client: BRISTOL-MYERS SQUIBB COMPANY
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Client expense: — · Firm income: $80,000
Matched citations: H.R.4299
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Client expense: — · Firm income: $80,000
Matched citations: H.R.5509
Community Health Center Drug Pricing Protection Act
2026 · third_quarter · Client: BRISTOL-MYERS SQUIBB COMPANY
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Client expense: — · Firm income: $80,000
Matched citations: H.R.7391
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Client: TAKEDA PHARMACEUTICALS AMERICA INC
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R.4299
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
H.R.1: One Big Beautiful Bill Act (Public Law 119-21). Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. Center for Medicare and Medicaid Innovation (CMMI) policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. IPAY and Maximum Fair Prices policy issues. Medicaid rebate policy issues. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. IRA price negotiation expansion policy issues.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1
Maintaining Investments in New Innovation Act
2026 · third_quarter · Client: NOVARTIS, INC.
Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues. H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025. Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. Medicaid rebate policy issues.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1672
Source: Senate LDA